Monthly Archives: May 2013

Biothera Expands Understanding of Imprime PGG Mechanism of Action

Research presented to the American Association of Immunologists EAGAN, MN — May 7, 2013 — Biothera researchers have determined that complement receptor 1 plays a critical role in the ability of Imprime PGG®, Biothera’s developmental immunomodulator drug, to engage and direct human neutrophils and monocytes in the fight against cancer. Previous studies had demonstrated that Imprime PGG, a patented yeast-derived soluble β-glucan, bound to human...

Read More